LB998 Follicular regeneration in response to wounding in ccca

Abstract

Hyperpigmentation of the skin is an important condition which is difficult to treat. It is caused by many factors such as sun exposure, aging, inflammation and genetic background. Correction of hyperpigmentary condition requires control of all stages of melanin lifecycle including melanocyte activation, melanosome development, melanin production, melanin distribution and epidermal turnover. We have developed a new product with a combination of ingredients that can modulate these key pathways. The goal of the study was to evaluate the effect of pigmentation correcting serum (LYT2) on various pathways involved in the melanin lifecycle. MEL-300-B (MatTek) constructed skin tissues were used for this study. Samples were collected after two weeks and evaluated for melanin quantification, gene expression of key targets and histological assessments. LYT2-treated tissues showed a reduction in melanin content by 45%AE7.65% compared to control. The expression of proopiomelanocortin (POMC) and microphthalmia transcription factor (MITF) genes which are involved with melanocyte activation showed down-regulation by 67.7% and 53.9%, respectively. Key genes of melanosome development, Melan-A, showed a 39.9% down-regulation. Melanin synthesis genes tyrosinase (TYR), tyrosinase related protein 1 (TYRP1) and TYRP2 also showed down-regulation of 53.4%, 57.5% and 34.8% respectively. Melanosome transfer inhibitory genes dickkopf-related pretein-1 (DKK-1) showed a 1236% upregulation. Histological analysis with Fontana Masson staining showed reduction of melanin particles compared to controls. These results indicate that newly developed pigmentation correcting serum (LYT2) is targeting multiple key pathways to control hyperpigmentation in the skin.